Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7

Nature

Volumn 391, Issue 6670, 1998, Pages 859-865

  Lee, Jie Oh ^b   Russo, Alicia A ^a   Pavletich, Nikola P ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR; CYCLIN A; CYCLIN DEPENDENT KINASE; CYCLINE; ONCOPROTEIN; RETINOBLASTOMA PROTEIN;

ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FOLDING; RETINOBLASTOMA; TUMOR SUPPRESSOR GENE; WART VIRUS;

AMINO ACID SEQUENCE; BINDING SITES; CONSERVED SEQUENCE; CRYSTALLOGRAPHY, X-RAY; CYCLINS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEOPLASMS; ONCOGENE PROTEINS, VIRAL; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; RETINOBLASTOMA PROTEIN;

GALLUS GALLUS; HUMAN PAPILLOMA VIRUS; HUMAN PAPILLOMAVIRUS TYPES;

EID: 2642601106     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/36038     Document Type: Article

References (48)

1. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell 81, 323-330 (1995).
2. Yandell, D. W. et al. Oncogenic point mutations in the human retinoblastoma gene: their application to genetic counseling. New Engl. J. Med. 321, 1689-1695 (1989).
3. Horowotiz, J. M. et al. Point mutational inactivation of the retinoblastoma antioncogene. Science 243, 937-940 (1989).
4. Kaye, F. J., Kratzke, R. A., Ferster, J. L. & Horowitz, J. M. A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. Proc. Natl Acad. Sci. USA 87, 6922-6926 (1990).
5. Onadim, Z., Hogg, A., Baird, P. N. & Cowell, J. K. Oncogenic point mutations in exon 20 of the RB1 gene in families showing incomplete penetrance and mild expression of the retinoblastoma phenotype. Proc. Natl Acad. Sci. USA 89, 6177-6181 (1992).
6. Dyson, N., Howley, P. M., Munger, K. & Harlow, E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243, 934-937 (1989).
7. zur Hausen, H. Papillomavirus infections: a major cause of human cancers. Biochim. Biophys. Acta 1288, f55-f58 (1996).
8. Bookstein, R., Shew, J. Y., Chen, P. L., Scully, P. & Lee, W. H. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247, 712-715 (1990).
9. Huang, H. J. et al. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242, 1563-1566 (1988).
10. Qin, X. Q., Chittenden, T., Livingston, D. M. & Kaelin, W. G. Jr Identification of a growth suppression domain within the retinoblastoma gene product. Genes Dev. 6, 953-964 (1992).
11. Goodrich, D. W., Wang, N. P., Qian, Y. W., Lee, E. Y. & Lee, W. H. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 67, 293-302 (1991).
12. Hinds, P. W. et al. Regulation of the retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70, 993-1006 (1992).
13. Buchkovich, K., Duffy, L. A. & Harlow, E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 58, 1097-1105 (1989).
14. Helin, K. et al. A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F. Cell 70, 33-50 (1992).
15. Kaelin, W. G. Jr et al. Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell 70, 351-364 (1992).
16. Hiebert, S. W., Chellappan, S. P., Horowitz, J. M. & Nevins, J. R. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes. Dev. 6, 177-185 (1992).
17. Flemington, E. K., Speck, S. H. & Kaelin, W. G. Jr E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proc. Natl Acad. Sci. USA 90, 6914-6918 (1993).
18. Helin, K., Harlow, E. & Fattaey, A. Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. Mol. Cell. Biol. 13, 6501-6508 (1993).
19. Weintraub, S. J. et al. Mechanism of active transcriptional repression by the retinoblastoma protein. Nature 375, 812-815 (1995).
20. Sellers, W. R., Rodgers, J. W. & Kaelin, W. G. Jr A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites. Proc. Natl Acad. Sci. USA 92, 11544-11548 (1995).
21. Herber, R., Liem, A., Pilot, H. & Lambert, P. F. Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. J. Virol. 70, 1873-1881 (1996).
22. Chellappan, S. et al. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc. Natl Acad. Sci. USA 89, 4549-4553 (1992).
23. Munger, K. et al. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8, 4099-4105 (1989).
24. DeCaprio, J. A. et al. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54, 275-283 (1988).
25. Whyte, P. et al. Association between an oncogene and an anti-oncogene: the advenovirus E1A proteins bind to the retinoblastoma gene product. Nature 334, 124-129 (1988).
26. Gulliver, G. A., Herber, R. L., Liem, A. & Lambert, P. F. Both conserved region 1 (CR1) and CR2 of the human papillomavirus type 16 E7 oncogene are required for induction of epidermal hyperplasia and tumor formation in transgenic mice. J. Virol. 71, 5905-5914 (1977).
27. Shan, B., Durfee, T. & Lee, W. H. Disruption of RB/E2F-1 interaction by single point mutations in E2F-1 enhances S-phase entry and apoptosis. Proc. Natl Acad. Sci. USA 93, 679-684 (1996).
28. Hu, Q. J., Dyson, N. & Harlow, E. The regions of the retinoblastoma protein needed for binding to adenovirus E1A or SV40 large T antigen are common sites for mutations. EMBO J. 9, 1147-1155 (1990).
29. Kaelin, W. G. Jr, Ewen, M. E. & Livingston, D. M. Definition of the minimal simian virus 40 large T antigen- and adenovirus E1A-binding domain in the retinoblastoma gene product. Mol. Cell. Biol. 10, 3761-3769 (1990).
30. Huang, S., Wang, N. P., Tseng, B. Y., Lee, W. H. & Lee, E. H. Two distinct and frequently mutated regions of retinoblastoma protein are required for binding to SV40 T antigen. EMBO J. 9, 1815-1822 (1990).
31. Jones, R. E. et al. Identification of HPV-16 E7 peptides that are potent antagonists of E7 binding to the retinoblastoma suppressor protein. J. Biol. Chem. 265, 12782-12785 (1990).
32. Chow, K. N. & Dean, D. C. Domains A and B in the Rb pocket interact to form a transcriptional repressor motif. Mol. Cell. Biol. 16, 4862-4868 (1996).
33. Kim, H. Y. & Cho, Y. Structural similarity between the pocket region of retinoblastoma tumour suppressor and the cyclin-box. Nature Struct. Biol. 4, 390-395 (1997).
34. Gibson, T. J., Thompson, J. D., Blocker, A. & Kouzarides, T. Evidence for a protein domain superfamily shared by the cyclins, TFIIB and RB/p107. Nucleic Acids Res. 22, 946-952 (1994).
35. Jeffrey, P. D. et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376, 313-320 (1995).
36. Nikolov, D. B. et al. Crystal structure of a TFIIB-TBP-TATA-element ternary complex. Nature 377, 119-128 (1995).
37. Grafi, G. et al. A maize cDNA encoding a member of the retinoblastoma protein family: involvement in endoreduplication. Proc. Natl Acad. Sci. USA 93, 8962-8967 (1996).
38. Dyson, N., Buchkovich, K., Whyte, P. & Harlow, E. The cellular 107K protein that binds to adenovirus E1A also associates with the large T antigens of SV40 and JC virus. Cell 58, 249-255 (1989).
39. Kratzke, R. A. et al. Partial inactivation of the RB product in a family with incomplete penetrance of familial retinoblastoma and benign retinal tumors. Oncogene 9, 1321-1326 (1994).
40. Kitagawa, M. et al. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J. 15, 7060-7069 (1996).
41. Knudsen, E. S. & Wang, J. Y. J. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J. Biol. Chem. 271, 8313-8320 (1996).
42. O'Connor, R. J. & Hearing, P. Mutually exclusive interaction of the adenovirus E4-6/7 protein and the retinoblastoma gene product with internal domains of E2F-1 and DP-1. J. Virol. 68, 6848-6862 (1994).
43. Wu, E. W., Clemens, K. E., Heck, D. V. & Munger, K. The human papillomavirus E7 oncoprotein and the cellular transcription factor E2F bind to separate sites on the retinoblastoma tumor suppressor protein. J. Virol. 67, 2402-2407 (1993).
44. Ikeda, M. A. & Nevins, J. R. Identification of distinct roles for separate E1A domains in disruption of E2F complexes. Mol. Cell. Biol. 13, 7029-7035 (1993).
45. Fattaey, A. R., Harlow, E. & Helin, K. Independent regions of adenovirus E1A are required for binding to and dissociation of E2F-protein complexes. Mol. Cell. Biol. 13, 7267-7277 (1993).
46. Collaborative Computational Project B. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D 50, 760-763 (1994).
47. Jones, T. A., Zhou, J.-Y., Cowan, S. W. & Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of erros in these models. Acta Crystallogr. A 47, 110-119 (1991).
48. Brunger, A. T. X-PLOR, a System for Crystallography and NMR (Yale Univ. Press, New Haven, CT, 1991).